GSA Capital Partners’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$120K Buy
98,413
+43,718
+80% +$51.1K 0.01% 1685
2026
Q2
$59K Buy
+54,695
New +$160K ﹤0.01% 1652
2026
Q1
– Sell
-20,889
Closed -$74K – 1671
2025
Q4
$74K Buy
+20,889
New +$84.8K 0.01% 1555
2023
Q4
– Sell
-121,897
Closed -$109K – 1447
2023
Q3
$109K Buy
121,897
+13,012
+12% +$17.3K 0.01% 1377
2023
Q2
$234K Buy
108,885
+85,237
+360% +$192K 0.02% 1181
2023
Q1
$46K Buy
+23,648
New +$87.2K ﹤0.01% 1404

Other funds holding ADCT

GSA Capital Partners's ADCT Position: Q3 2026 in Review

GSA Capital Partners increased its ADC Therapeutics (ADCT) stake by 80% in Q3 2026, buying an estimated $51.1K and bringing the position to 98,413 shares worth $120K. The position accounts for 0.01% of the portfolio, ranked #1685.

GSA Capital Partners first reported a position in ADCT in Q1 2023 and has held it in 6 quarters since. The position peaked at $234K in Q2 2023. 110 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • GSA Capital Partners held 98,413 shares of ADC Therapeutics worth $120K as of Q3 2026.
  • GSA Capital Partners bought 43,718 ADC Therapeutics shares in Q3 2026, an estimated $51.1K.
  • ADC Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1685 holding.
  • GSA Capital Partners first reported a position in ADC Therapeutics in Q1 2023 and has held it in 6 quarters since.
  • GSA Capital Partners's ADC Therapeutics position peaked at $234K in Q2 2023.
  • 110 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.